Is NVDA a sell? Buy this stock instead before Dec 3

After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is making headlines for last week's new earnings report – which revealed the AI juggernaut nearly doubled their profits in the last year alone.

A 50-year Wall Street veteran gives his answer Nvidia, right here...

James Healy Biography and Net Worth

Director of Karuna Therapeutics

Dr. Jim Healy is a General Partner at Sofinnova Investments. Dr. Healy finances companies that are developing potentially important therapies that could be transformative for patients. He has funded companies where eleven products were approved by the FDA or EMA. Eighteen of his investments have gone public and ten have been acquired as private or public companies.

Prior to Sofinnova, Dr. Healy worked at Bayer and Sanderling. In 2011 he received the IBF Innovator Award for his investment in Amarin. In 2012 Xconomy named him one the leading “Young and Proven Biotech VC’s”. In 2013, Fortune selected him as one of the top life science investors and in 2015 he received a Healthcare and Lifesciences 50 award from Irish America. He has lectured on entrepreneurship at Stanford University and served on the boards of the Executive Committee at UC Berkeley, the National Venture Capital Association (NVCA) and the Biotechnology Innovation Organization (BIO). Dr. Healy is currently on the board of directors of Ascendis Pharma A/S (NASDAQ: ASND), Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), CinCor Pharma Inc. (NASDAQ: CINC), NuCana plc (NASDAQ: NCNA), Natera, Inc. (NASDAQ: NTRA), and Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB).

Dr. Healy received his B.A.in Molecular Biology and B.A. in Scandinavian Studies from UC Berkeley, where he graduated with Honors and received the Departmental Citation. He subsequently completed the NIH sponsored Medical Scientist Training Program and received his MD and PhD in Immunology from Stanford University where he received the Novartis Foundation Bursary Award and was a Beckman Scholar. He authored or co-authored thirteen scientific articles and reviews, including three papers published in Nature.

What is James Healy's net worth?: The estimated net worth of James Healy is at least $13.47 million as of July 1st, 2024. Dr. Healy owns 40,851 shares of Karuna Therapeutics stock worth more than $13,473,885 as of November 26th. This net worth approximation does not reflect any other assets that Dr. Healy may own. Learn More about James Healy's net worth.
How do I contact James Healy?: The corporate mailing address for Dr. Healy and other Karuna Therapeutics executives is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. Karuna Therapeutics can also be reached via phone at (857) 449-2244 and via email at [email protected]. Learn More on James Healy's contact information.
Has James Healy been buying or selling shares of Karuna Therapeutics?: James Healy has not been actively trading shares of Karuna Therapeutics during the last quarter. Most recently, James Healy sold 6,027 shares of the business's stock in a transaction on Friday, January 13th. The shares were sold at an average price of $199.90, for a transaction totalling $1,204,797.30. Following the completion of the sale, the director now directly owns 32,500 shares of the company's stock, valued at $6,496,750. Learn More on James Healy's trading history.
Who are Karuna Therapeutics' active insiders?: Karuna Therapeutics' insider roster includes Stephen Brannan (Insider), James Healy (Director), Troy Ignelzi (CFO), Jeffrey Jonas (Director), Andrew Miller (COO), Laurie Olson (Director), Atul Pande (Director), Steven Paul (CEO), and Heather Preston (Director). Learn More on Karuna Therapeutics' active insiders.
Are insiders buying or selling shares of Karuna Therapeutics?: In the last twelve months, insiders at the sold shares 4 times. They sold a total of 35,000 shares worth more than $9,948,200.00. The most recent insider tranaction occured on March, 8th when insider Stephen K Brannan sold 5,000 shares worth more than $1,591,700.00. Insiders at Karuna Therapeutics own 13.2% of the company. Learn More about insider trades at Karuna Therapeutics.
Information on this page was last updated on 3/8/2024.

James Healy Insider Trading History at Karuna Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/13/2023	Sell	6,027	$199.90	$1,204,797.30	32,500
6/29/2022	Buy	47,777	$123.04	$5,878,482.08	2,000,218
4/1/2022	Buy	47	$129.38	$6,080.86	683
7/2/2021	Buy	636	$117.80	$74,920.80
9/8/2020	Buy	504	$73.00	$36,792.00
11/25/2019	Buy	156,250	$96.00	$15,000,000.00
7/2/2019	Buy	700,000	$16.00	$11,200,000.00

James Healy Buying and Selling Activity at Karuna Therapeutics

Karuna Therapeutics Company Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $329.83

$329.83

50 Day Range

MA: $327.01

$313.97

$329.83

2 Week Range

Now: $329.83

$158.38

$329.99

Volume

5 shs

Average Volume

832,048 shs

Market Capitalization

$12.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18